ZYUS Life Sciences’ (ZYU) “Buy” Rating Reiterated at Roth Capital
Roth Capital reiterated their buy rating on shares of ZYUS Life Sciences (CVE:ZYU – Free Report) in a report published on Thursday, PriceTargets.com reports. Separately, Stifel Canada reissued a speculative buy rating on shares of ZYUS Life Sciences in a research note on Friday, January 26th. Check Out Our Latest Research Report on ZYUS Life […]
More Stories
HUD Audit Reveals $5.8 Billion in Potentially Improper Rental Assistance Payments Under Biden
By Naveen Athrappully There was a “significant misuse” of taxpayer funds under the Biden administration concerning rental assistance, which resulted...
Hundreds of Flights in the Caribbean Canceled After Venezuela Strike
By Jacki Thrapp Airlines have cancelled hundreds of flights in the Caribbean after the United States captured Venezuelan President Nicolás...
Maduro and His Wife Indicted in US Federal Court
By T.J. Muscaro Nicolás Maduro and his wife, Cilia Flores, were indicted in the Southern District of New York, U.S....
Swiss Prosecutors Investigate Bar Managers After Deadly Ski Resort Fire
By Jacki Thrapp Swiss authorities opened a criminal investigation into two bar managers after a fire at a ski resort...
US Agencies Terminate ‘Wasteful’ Contracts Worth $1.6 Billion Ceiling Value: DOGE
By Naveen Athrappully Over the past three days, federal agencies have terminated and descoped 55 “wasteful” contracts with a ceiling...
AI Spending Fuels High Tech Growth in 2025, But a Crucial Test Lies Ahead
By Panos Mourdoukoutas Heavy investment in artificial intelligence (AI) infrastructure accounted for the majority of IT spending in 2025. It...